Bilastine is a highly selective, long-acting, non-sedating antihistamine with strong affinity for H1 receptors—approximately 3 times higher than cetirizine and 5 times higher than fexofenadine. Even at high concentrations, it shows no affinity for 30 other receptor types, including muscarinic, serotonergic, dopaminergic, and noradrenergic receptors, as well as other histamine receptor subtypes (H2, H3, H4).
Bilastine exhibits an excellent safety profile and favorable pharmacokinetic properties. It remains pharmacologically active without undergoing metabolism. The drug is excreted mainly through feces (≈66%) and urine (≈28%), indicating both systemic and non-systemic elimination pathways.

100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
It also provides relief from symptoms associated with hay fever, such as sneezing, itching, nasal congestion or discharge, and red or watery eyes.
Adults and adolescents (≥12 years):
20 mg tablet once daily for allergic rhinitis, allergic rhinoconjunctivitis, or urticaria.
It should be taken on an empty stomach with water for optimal absorption.
If a dose is missed, continue with the next scheduled dose—do not double the dose.
Children (6–11 years):
10 mg mouth-dissolving tablet, taken once daily, for symptomatic relief of allergic rhinitis, allergic rhinoconjunctivitis, and urticaria.
The tablet can be placed on the tongue to dissolve or dispersed in a teaspoon of water before swallowing.
Do not exceed 10 mg daily.
Children (2–11 years):
4 mL once daily as directed.
(Use only as prescribed by a registered physician.)
The most commonly reported adverse effects are headache, dizziness, somnolence, and fatigue, which occur at a frequency similar to that of the placebo.
Concurrent use of Zilas with ketoconazole, erythromycin, cyclosporine, or diltiazem may increase Bilastine levels, but these changes do not significantly affect safety.
When taken with alcohol or lorazepam (3 mg), Bilastine does not enhance sedative or psychomotor-depressant effects.
Contraindicated in patients with hypersensitivity to Bilastine or any component of the formulation.
Pregnancy: Limited human data available. Animal studies show no reproductive or developmental harm, but use is not recommended during pregnancy as a precaution.
Lactation: Unknown if excreted in human milk. A decision should be made considering the benefit to the mother versus the risk to the infant.
Zilas does not impair driving performance, but in rare cases of mild drowsiness may occur.
Elderly patients (≥65 years) show comparable safety and efficacy to younger adults.
In severe renal impairment, Bilastine plasma concentration remains below safety thresholds, and no dosage adjustment is required.
Since elimination is mainly renal, hepatic impairment is not expected to affect clearance significantly.
Store below 30°C, away from light and moisture. Keep out of the reach of children.
⚠️Disclaimer:
At ePharma, we’re committed to providing accurate and accessible health information. However, all content is intended for informational purposes only and should not replace medical advice from a qualified physician. Please consult your healthcare provider for personalized guidance. We aim to support, not substitute, the doctor-patient relationship.